Enterprise Value
40.56B
Cash
8.923B
Avg Qtr Burn
N/A
Short % of Float
6.36%
Insider Ownership
9.61%
Institutional Own.
68.33%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
mRNA-1273 Details COVID-19 | Approved Quarterly sales | |
mRNA-1345 Details Respiratory syncytial virus | BLA Submission | |
mRNA-1010 Details Influenza | Phase 3 Data readout | |
mRNA-1283 Details COVID-19 | Phase 3 Data readout | |
mRNA-1647 Details Cytomegalovirus | Phase 3 Interim Update | |
mRNA-4157/V940 +KEYTRUDA Details Cancer, Melanoma | Phase 3 Initiation | |
mRNA-1468 Details Varicella-zoster virus | Phase 1/2 Interim update | |
mRNA-3927 Details Propionic acidemia | Phase 1/2 Update | |
mRNA-1574 Details (HIV) human immunodeficiency virus | Phase 1 Data readout |